NCT06746194 The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy
| NCT ID | NCT06746194 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ruijin Hospital |
| Condition | Hepatocellular Carcinoma (HCC) |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-12-03 |
| Primary Completion | 2028-12-31 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This study aims to investigate the value of 68Ga-FAPI PET/CT in the efficacy evaluation of advanced unresectable hepatocellular carcinoma patients undergoing systemic antitumor therapy.
Eligibility Criteria
Inclusion Criteria: 1. Pathological and clinical diagnosis of advanced unresectable hepatocellular carcinoma patients. 2. Signed and dated informed consent form. 3. Commitment to comply with research procedures and co-operation in the implementation of the full research process. 4. Aged 18-75 years old. Exclusion Criteria: 1. Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc. 2. Intestinal perforation, complete intestinal obstruction 3. Pregnant women and women who may be pregnant, women who are breastfeeding. 4. Non-compliant person
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.